Skip to main content
Publications
Shamarina D, Sluga-O'Callaghan M , Kassianos G, Marijam A, Dave V, Davenport E , Andani A, Curran D, Dewda P, Steffen R. Knowledge, attitudes, and practices of European healthcare professionals towards hepatitis A and hepatitis B vaccination in at-risk adults . Vaccines-Basel. 2023 Oct 26;11(1645):1-19. doi: 10.3390/vaccines11111645
Goyal RK , Jain P, Nagar SP , Le H, Kabadi SM, Davis K , Kaye JA, Du XL, Wang M. Real-world evidence on survival, adverse events, and health care burden in Medicare patients with mantle cell lymphoma . Leuk Lymphoma. 2021 Jun;62(6):1325-34. doi: 10.1080/10428194.2021.1919662
Nastoupil LJ, Sinha R, Byrtek M, Ziemiecki R , Taylor M, Friedberg JW, Koff JL, Link BK, Cerhan JR, Dawson KL, Flowers CR. Comparison of the effectiveness of frontline chemoimmunotherapy regimens for follicular lymphoma used in the United States . Leuk Lymphoma. 2015 May;56(5):1295-302. doi: 10.3109/10428194.2014.953144
Francois C, Danchenko N, Williams VS , Nelson LM , Williams NJ, Yarr SR , DiBenedetti DB , Lancon C. Psychometric evaluation of the depression and family functioning scale (DFFS) . Poster presented at the Second Meeting on Patient Reported Outcomes and Person Centered Care in Mental Health – Diagnosis, Prevention and Treatment in Mental Health: Effectiveness and Comparative Effectiveness; September 26, 2014. Washington, DC. [abstract] J Ment Health Policy Econ. 2014 Sep; 17(Suppl 1):S5-6.
Varadhachary GR, Spector Y, Abbruzzese JL, Rosenwald S, Wang H, Aharonov R, Carlson HR, Cohen D, Karanth S , Macinskas J, Lenzi R, Chajut A, Edmonston TB, Raber MN. Prospective gene signature study using microRNA to identify the tissue of origin in patients with carcinoma of unknown primary . Clin Cancer Res. 2011 Jun 15;17(12):4063-70. doi: 10.1158/1078-0432.CCR-10-2599
LoRusso PM, Herbst RS, Rischin D, Ranson M, Calvert H, Raymond E, Kieback D, Kaye S, Gianni L, Harris A, Bjork T, Maddox A, Rothenberg ML, Small EJ, Rubin EH, Feyereislova A, Heyes A , Averbuch SD, Ochs J, Baselga J. Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors . Clin Cancer Res. 2003 Jun 1;9(6):2040-8.